http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 18 Jun 2026 16:58:01 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Teva+submits+NDA+for+ecopipam+to+treat+pediatric+Tourette+syndrome/26666962.html <p>Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ecopipam, an investigational treatment for pediatric Tourette syndrome, the company announced June 18, 2026.</p><p>Ecopipam is a selective dopamine D1 receptor antagonist and has received FDA Orphan Drug and Fast Track designations for the treatment of pediatric patients with Tourette syndrome. Orphan Drug designation applies to conditions affecting populations of 200,000 or fewer.</p><p>The NDA is supported by Phase 3 data published in <em>JAMA Neurology</em>, which showed ecopipam significantly delayed time to relapse compared with placebo in pediatric patients http://www.streetinsider.com/Corporate+News/Teva+submits+NDA+for+ecopipam+to+treat+pediatric+Tourette+syndrome/26666962.html Thu, 18 Jun 2026 16:58:01 -0400 TEVA http://www.streetinsider.com/Press+Releases/Teva+Submits+NDA+for+Ecopipam%2C+a+First-in-Class+Investigational+Therapy+for+Pediatric+Tourette+Syndrome/26666954.html <ul type="disc"><li style="margin-bottom:8pt;">NDA submission supported by positive Phase 3 data recently published in JAMA Neurology.</li><li style="margin-bottom:8pt;">Ecopipam is a first-in-class selective dopamine D1 receptor antagonist with a novel mechanism of action and has received FDA Orphan Drug and Fast Track designations</li><li style="margin-bottom:8pt;">Ecopipam could be the first FDA-approved treatment option for pediatric Tourette syndrome in more than a decade, if approved.<br/></li></ul> <p>TEL AVIV, Israel, June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ecopipam, a http://www.streetinsider.com/Press+Releases/Teva+Submits+NDA+for+Ecopipam%2C+a+First-in-Class+Investigational+Therapy+for+Pediatric+Tourette+Syndrome/26666954.html Thu, 18 Jun 2026 16:56:00 -0400 A.06822034 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Press+Releases/Teva+Submits+NDA+for+Ecopipam%2C+a+First-in-Class+Investigational+Therapy+for+Pediatric+Tourette+Syndrome/26666954.html <ul type="disc"><li style="margin-bottom:8pt;">NDA submission supported by positive Phase 3 data recently published in JAMA Neurology.</li><li style="margin-bottom:8pt;">Ecopipam is a first-in-class selective dopamine D1 receptor antagonist with a novel mechanism of action and has received FDA Orphan Drug and Fast Track designations</li><li style="margin-bottom:8pt;">Ecopipam could be the first FDA-approved treatment option for pediatric Tourette syndrome in more than a decade, if approved.<br/></li></ul> <p>TEL AVIV, Israel, June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ecopipam, a http://www.streetinsider.com/Press+Releases/Teva+Submits+NDA+for+Ecopipam%2C+a+First-in-Class+Investigational+Therapy+for+Pediatric+Tourette+Syndrome/26666954.html Thu, 18 Jun 2026 16:56:00 -0400 A.06822034 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Press+Releases/Teva+Submits+NDA+for+Ecopipam%2C+a+First-in-Class+Investigational+Therapy+for+Pediatric+Tourette+Syndrome/26666954.html <ul type="disc"><li style="margin-bottom:8pt;">NDA submission supported by positive Phase 3 data recently published in JAMA Neurology.</li><li style="margin-bottom:8pt;">Ecopipam is a first-in-class selective dopamine D1 receptor antagonist with a novel mechanism of action and has received FDA Orphan Drug and Fast Track designations</li><li style="margin-bottom:8pt;">Ecopipam could be the first FDA-approved treatment option for pediatric Tourette syndrome in more than a decade, if approved.<br/></li></ul> <p>TEL AVIV, Israel, June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ecopipam, a http://www.streetinsider.com/Press+Releases/Teva+Submits+NDA+for+Ecopipam%2C+a+First-in-Class+Investigational+Therapy+for+Pediatric+Tourette+Syndrome/26666954.html Thu, 18 Jun 2026 16:56:00 -0400 A.06822034 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Press+Releases/Teva+Submits+NDA+for+Ecopipam%2C+a+First-in-Class+Investigational+Therapy+for+Pediatric+Tourette+Syndrome/26666954.html <ul type="disc"><li style="margin-bottom:8pt;">NDA submission supported by positive Phase 3 data recently published in JAMA Neurology.</li><li style="margin-bottom:8pt;">Ecopipam is a first-in-class selective dopamine D1 receptor antagonist with a novel mechanism of action and has received FDA Orphan Drug and Fast Track designations</li><li style="margin-bottom:8pt;">Ecopipam could be the first FDA-approved treatment option for pediatric Tourette syndrome in more than a decade, if approved.<br/></li></ul> <p>TEL AVIV, Israel, June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ecopipam, a http://www.streetinsider.com/Press+Releases/Teva+Submits+NDA+for+Ecopipam%2C+a+First-in-Class+Investigational+Therapy+for+Pediatric+Tourette+Syndrome/26666954.html Thu, 18 Jun 2026 16:56:00 -0400 A.06822034 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Press+Releases/Teva+Submits+NDA+for+Ecopipam%2C+a+First-in-Class+Investigational+Therapy+for+Pediatric+Tourette+Syndrome/26666954.html <ul type="disc"><li style="margin-bottom:8pt;">NDA submission supported by positive Phase 3 data recently published in JAMA Neurology.</li><li style="margin-bottom:8pt;">Ecopipam is a first-in-class selective dopamine D1 receptor antagonist with a novel mechanism of action and has received FDA Orphan Drug and Fast Track designations</li><li style="margin-bottom:8pt;">Ecopipam could be the first FDA-approved treatment option for pediatric Tourette syndrome in more than a decade, if approved.<br/></li></ul> <p>TEL AVIV, Israel, June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ecopipam, a http://www.streetinsider.com/Press+Releases/Teva+Submits+NDA+for+Ecopipam%2C+a+First-in-Class+Investigational+Therapy+for+Pediatric+Tourette+Syndrome/26666954.html Thu, 18 Jun 2026 16:56:00 -0400 A.06822034 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Globe+Newswire/Teva+Submits+NDA+for+Ecopipam%2C+a+First-in-Class+Investigational+Therapy+for+Pediatric+Tourette+Syndrome/26666954.html <ul type="disc"><li style="margin-bottom:8pt;">NDA submission supported by positive Phase 3 data recently published in JAMA Neurology.</li><li style="margin-bottom:8pt;">Ecopipam is a first-in-class selective dopamine D1 receptor antagonist with a novel mechanism of action and has received FDA Orphan Drug and Fast Track designations</li><li style="margin-bottom:8pt;">Ecopipam could be the first FDA-approved treatment option for pediatric Tourette syndrome in more than a decade, if approved.<br/></li></ul> <p>TEL AVIV, Israel, June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ecopipam, a http://www.streetinsider.com/Globe+Newswire/Teva+Submits+NDA+for+Ecopipam%2C+a+First-in-Class+Investigational+Therapy+for+Pediatric+Tourette+Syndrome/26666954.html Thu, 18 Jun 2026 16:56:00 -0400 A.06822034 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Globe+Newswire/Teva+Submits+NDA+for+Ecopipam%2C+a+First-in-Class+Investigational+Therapy+for+Pediatric+Tourette+Syndrome/26666954.html <ul type="disc"><li style="margin-bottom:8pt;">NDA submission supported by positive Phase 3 data recently published in JAMA Neurology.</li><li style="margin-bottom:8pt;">Ecopipam is a first-in-class selective dopamine D1 receptor antagonist with a novel mechanism of action and has received FDA Orphan Drug and Fast Track designations</li><li style="margin-bottom:8pt;">Ecopipam could be the first FDA-approved treatment option for pediatric Tourette syndrome in more than a decade, if approved.<br/></li></ul> <p>TEL AVIV, Israel, June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ecopipam, a http://www.streetinsider.com/Globe+Newswire/Teva+Submits+NDA+for+Ecopipam%2C+a+First-in-Class+Investigational+Therapy+for+Pediatric+Tourette+Syndrome/26666954.html Thu, 18 Jun 2026 16:56:00 -0400 A.06822034 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Globe+Newswire/Teva+Submits+NDA+for+Ecopipam%2C+a+First-in-Class+Investigational+Therapy+for+Pediatric+Tourette+Syndrome/26666954.html <ul type="disc"><li style="margin-bottom:8pt;">NDA submission supported by positive Phase 3 data recently published in JAMA Neurology.</li><li style="margin-bottom:8pt;">Ecopipam is a first-in-class selective dopamine D1 receptor antagonist with a novel mechanism of action and has received FDA Orphan Drug and Fast Track designations</li><li style="margin-bottom:8pt;">Ecopipam could be the first FDA-approved treatment option for pediatric Tourette syndrome in more than a decade, if approved.<br/></li></ul> <p>TEL AVIV, Israel, June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ecopipam, a http://www.streetinsider.com/Globe+Newswire/Teva+Submits+NDA+for+Ecopipam%2C+a+First-in-Class+Investigational+Therapy+for+Pediatric+Tourette+Syndrome/26666954.html Thu, 18 Jun 2026 16:56:00 -0400 A.06822034 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Globe+Newswire/Teva+Submits+NDA+for+Ecopipam%2C+a+First-in-Class+Investigational+Therapy+for+Pediatric+Tourette+Syndrome/26666954.html <ul type="disc"><li style="margin-bottom:8pt;">NDA submission supported by positive Phase 3 data recently published in JAMA Neurology.</li><li style="margin-bottom:8pt;">Ecopipam is a first-in-class selective dopamine D1 receptor antagonist with a novel mechanism of action and has received FDA Orphan Drug and Fast Track designations</li><li style="margin-bottom:8pt;">Ecopipam could be the first FDA-approved treatment option for pediatric Tourette syndrome in more than a decade, if approved.<br/></li></ul> <p>TEL AVIV, Israel, June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ecopipam, a http://www.streetinsider.com/Globe+Newswire/Teva+Submits+NDA+for+Ecopipam%2C+a+First-in-Class+Investigational+Therapy+for+Pediatric+Tourette+Syndrome/26666954.html Thu, 18 Jun 2026 16:56:00 -0400 A.06822034 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Globe+Newswire/Teva+Submits+NDA+for+Ecopipam%2C+a+First-in-Class+Investigational+Therapy+for+Pediatric+Tourette+Syndrome/26666954.html <ul type="disc"><li style="margin-bottom:8pt;">NDA submission supported by positive Phase 3 data recently published in JAMA Neurology.</li><li style="margin-bottom:8pt;">Ecopipam is a first-in-class selective dopamine D1 receptor antagonist with a novel mechanism of action and has received FDA Orphan Drug and Fast Track designations</li><li style="margin-bottom:8pt;">Ecopipam could be the first FDA-approved treatment option for pediatric Tourette syndrome in more than a decade, if approved.<br/></li></ul> <p>TEL AVIV, Israel, June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ecopipam, a http://www.streetinsider.com/Globe+Newswire/Teva+Submits+NDA+for+Ecopipam%2C+a+First-in-Class+Investigational+Therapy+for+Pediatric+Tourette+Syndrome/26666954.html Thu, 18 Jun 2026 16:56:00 -0400 A.06822034 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/SEC+Filings/Form++144++++++++TEVA+PHARMACEUTICAL+INDU+++++++++++++++Filed+by%3A+Shields+Matthew/26666207.html si-local-file:///var/storage/secattach/20260618/26666207.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++TEVA+PHARMACEUTICAL+INDU+++++++++++++++Filed+by%3A+Shields+Matthew/26666207.html Thu, 18 Jun 2026 16:15:00 -0400 O.05029585 TEVA TEVA http://www.streetinsider.com/SEC+Filings/Form++144++++++++TEVA+PHARMACEUTICAL+INDU+++++++++++++++Filed+by%3A+Shields+Matthew/26666207.html si-local-file:///var/storage/secattach/20260618/26666207.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++TEVA+PHARMACEUTICAL+INDU+++++++++++++++Filed+by%3A+Shields+Matthew/26666207.html Thu, 18 Jun 2026 16:15:00 -0400 O.05029585 TEVA TEVA http://www.streetinsider.com/SEC+Filings/Form++144++++++++TEVA+PHARMACEUTICAL+INDU+++++++++++++++Filed+by%3A+Shields+Matthew/26666207.html si-local-file:///var/storage/secattach/20260618/26666207.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++TEVA+PHARMACEUTICAL+INDU+++++++++++++++Filed+by%3A+Shields+Matthew/26666207.html Thu, 18 Jun 2026 16:15:00 -0400 O.05029585 TEVA TEVA http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Immuneering+Corp++++++++++For%3A+Jun+15++Filed+by%3A+Hall+Brett+Matthew/26654291.html si-local-file:///var/storage/secattach/20260616/26654291.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Immuneering+Corp++++++++++For%3A+Jun+15++Filed+by%3A+Hall+Brett+Matthew/26654291.html Tue, 16 Jun 2026 16:15:00 -0400 IMRX O.05029585 O.59438130 TEVA http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Immuneering+Corp++++++++++For%3A+Jun+15++Filed+by%3A+Hall+Brett+Matthew/26654291.html si-local-file:///var/storage/secattach/20260616/26654291.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Immuneering+Corp++++++++++For%3A+Jun+15++Filed+by%3A+Hall+Brett+Matthew/26654291.html Tue, 16 Jun 2026 16:15:00 -0400 IMRX O.05029585 O.59438130 TEVA http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Immuneering+Corp++++++++++For%3A+Jun+15++Filed+by%3A+Hall+Brett+Matthew/26654291.html si-local-file:///var/storage/secattach/20260616/26654291.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Immuneering+Corp++++++++++For%3A+Jun+15++Filed+by%3A+Hall+Brett+Matthew/26654291.html Tue, 16 Jun 2026 16:15:00 -0400 IMRX O.05029585 O.59438130 TEVA http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Immuneering+Corp++++++++++For%3A+Jun+15++Filed+by%3A+Hall+Brett+Matthew/26654291.html si-local-file:///var/storage/secattach/20260616/26654291.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Immuneering+Corp++++++++++For%3A+Jun+15++Filed+by%3A+Hall+Brett+Matthew/26654291.html Tue, 16 Jun 2026 16:15:00 -0400 IMRX O.05029585 O.59438130 TEVA http://www.streetinsider.com/SEC+Filings/Form++4++++++++++TEVA+PHARMACEUTICAL+INDU++For%3A+Jun+11++Filed+by%3A+Kalif+Eliyahu+Sharon/26650956.html si-local-file:///var/storage/secattach/20260616/26650956.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++TEVA+PHARMACEUTICAL+INDU++For%3A+Jun+11++Filed+by%3A+Kalif+Eliyahu+Sharon/26650956.html Tue, 16 Jun 2026 08:28:00 -0400 O.05029585 TEVA TEVA http://www.streetinsider.com/SEC+Filings/Form++4++++++++++TEVA+PHARMACEUTICAL+INDU++For%3A+Jun+11++Filed+by%3A+Kalif+Eliyahu+Sharon/26650956.html si-local-file:///var/storage/secattach/20260616/26650956.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++TEVA+PHARMACEUTICAL+INDU++For%3A+Jun+11++Filed+by%3A+Kalif+Eliyahu+Sharon/26650956.html Tue, 16 Jun 2026 08:28:00 -0400 O.05029585 TEVA TEVA http://www.streetinsider.com/SEC+Filings/Form++4++++++++++TEVA+PHARMACEUTICAL+INDU++For%3A+Jun+11++Filed+by%3A+Kalif+Eliyahu+Sharon/26650956.html si-local-file:///var/storage/secattach/20260616/26650956.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++TEVA+PHARMACEUTICAL+INDU++For%3A+Jun+11++Filed+by%3A+Kalif+Eliyahu+Sharon/26650956.html Tue, 16 Jun 2026 08:28:00 -0400 O.05029585 TEVA TEVA http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Immuneering+Corp++++++++++For%3A+Jun+11/26647480.html si-local-file:///var/storage/secattach/20260615/26647480.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Immuneering+Corp++++++++++For%3A+Jun+11/26647480.html Mon, 15 Jun 2026 16:12:00 -0400 IMRX O.05029585 O.59438130 TEVA http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Immuneering+Corp++++++++++For%3A+Jun+11/26647480.html si-local-file:///var/storage/secattach/20260615/26647480.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Immuneering+Corp++++++++++For%3A+Jun+11/26647480.html Mon, 15 Jun 2026 16:12:00 -0400 IMRX O.05029585 O.59438130 TEVA http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Immuneering+Corp++++++++++For%3A+Jun+11/26647480.html si-local-file:///var/storage/secattach/20260615/26647480.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Immuneering+Corp++++++++++For%3A+Jun+11/26647480.html Mon, 15 Jun 2026 16:12:00 -0400 IMRX O.05029585 O.59438130 TEVA http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Immuneering+Corp++++++++++For%3A+Jun+11/26647480.html si-local-file:///var/storage/secattach/20260615/26647480.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Immuneering+Corp++++++++++For%3A+Jun+11/26647480.html Mon, 15 Jun 2026 16:12:00 -0400 IMRX O.05029585 O.59438130 TEVA